Terms: = Lymphoma AND MN1, Q10571, MGCR1-PEN, MGCR1, MGCR, dJ353E16_2, ENSG00000169184, 4330 AND Clinical Outcome
919 results:
1. Validation of genes for H-ARS severity prediction in leukemia patients - interspecies comparison, challenges, and promises.
Schwanke D; Valente M; Ostheim P; Schüle S; Bobyk L; Drouet M; Riccobono D; Magné N; Daguenet E; Stewart SJ; Muhtadi R; Port M; Abend M
Int J Radiat Biol; 2024; 100(4):527-540. PubMed ID: 38227483
[TBL] [Abstract] [Full Text] [Related]
2. The fifth edition of the WHO classification of mature B-cell neoplasms: open questions for research.
Coupland SE; Du MQ; Ferry JA; de Jong D; Khoury JD; Leoncini L; Naresh KN; Ott G; Siebert R; Xerri L;
J Pathol; 2024 Mar; 262(3):255-270. PubMed ID: 38180354
[TBL] [Abstract] [Full Text] [Related]
3. Biological signatures of the International Prognostic Index in diffuse large B-cell lymphoma.
Wang Y; Shi Q; Shi ZY; Tian S; Zhang MC; Shen R; Fu D; Dong L; Yi HM; Ouyang BS; Mu RJ; Cheng S; Wang L; Xu PP; Zhao WL
Blood Adv; 2024 Apr; 8(7):1587-1599. PubMed ID: 38170757
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of the cachexia index using a bioelectrical impedance analysis in elderly patients with non-Hodgkin's lymphoma: A single-center prospective study.
Okubo S; Shinmura K; Kadota S; Nakayasu M; Kurosawa S; Nakayama H; Sakurai A; Ito C; Aisa Y; Nakazato T
Ann Hematol; 2024 Mar; 103(3):823-831. PubMed ID: 38010408
[TBL] [Abstract] [Full Text] [Related]
5. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
6. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens.
Maura F; Boyle EM; Coffey D; Maclachlan K; Gagler D; Diamond B; Ghamlouch H; Blaney P; Ziccheddu B; Cirrincione A; Chojnacka M; Wang Y; Siegel A; Hoffman JE; Kazandjian D; Hassoun H; Guzman E; Mailankody S; Shah UA; Tan C; Hultcrantz M; Scordo M; Shah GL; Landau H; Chung DJ; Giralt S; Zhang Y; Arbini A; Gao Q; Roshal M; Dogan A; Lesokhin AM; Davies FE; Usmani SZ; Korde N; Morgan GJ; Landgren O
Nat Cancer; 2023 Dec; 4(12):1660-1674. PubMed ID: 37945755
[TBL] [Abstract] [Full Text] [Related]
7. Suspected primary bone marrow T-cell lymphoid neoplasia causing paraneoplastic hypercalcemia in 11 dogs (2014-2021).
Portanova A; Rout ED; Avery AC; Viall AK
J Am Vet Med Assoc; 2024 Mar; 262(3):1-9. PubMed ID: 37922707
[TBL] [Abstract] [Full Text] [Related]
8. clinical and prognostic role of sarcopenia based on masticatory muscle index on MR images in patients with extranodal natural killer/T cell lymphoma, nasal type.
Xu T; Li Y; Liu Y; Ning B; Wu H; Wei Y
Ann Hematol; 2023 Dec; 102(12):3521-3532. PubMed ID: 37702822
[TBL] [Abstract] [Full Text] [Related]
9. Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions.
de Mendoza C; Rando A; Miró E; Pena MJ; Rodríguez-Avial I; Ortega D; González-Praetorius A; Reina G; Pintos I; Pozuelo MJ; Soriano V;
J Clin Virol; 2023 Oct; 167():105578. PubMed ID: 37660433
[TBL] [Abstract] [Full Text] [Related]
10. MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and
Rodrigues JM; Hollander P; Schmidt L; Gkika E; Razmara M; Kumar D; Geisler C; Grønbæk K; Eskelund CW; Räty R; Kolstad A; Sundström C; Glimelius I; Porwit A; Jerkeman M; Ek S
Haematologica; 2024 Apr; 109(4):1171-1183. PubMed ID: 37646663
[TBL] [Abstract] [Full Text] [Related]
11. Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell lymphoma Failing Prior L-Asparaginase and PD-1 Blockade.
Tao R; Liu C; Zhang W; Zhu Y; Ma Y; Hao S
Oncologist; 2024 Jan; 29(1):e90-e96. PubMed ID: 37616529
[TBL] [Abstract] [Full Text] [Related]
12. clinical outcome of Mantle Cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression).
Scheubeck G; Jiang L; Hermine O; Kluin-Nelemans HC; Schmidt C; Unterhalt M; Rosenwald A; Klapper W; Evangelista A; Ladetto M; Jerkeman M; Ferrero S; Dreyling M; Hoster E
Leukemia; 2023 Sep; 37(9):1887-1894. PubMed ID: 37495776
[TBL] [Abstract] [Full Text] [Related]
13. PersonALL: a genetic scoring guide for personalized risk assessment in pediatric B-cell precursor acute lymphoblastic leukemia.
Bedics G; Egyed B; Kotmayer L; Benard-Slagter A; de Groot K; Bekő A; Hegyi LL; Bátai B; Krizsán S; Kriván G; Erdélyi DJ; Müller J; Haltrich I; Kajtár B; Pajor L; Vojcek Á; Ottóffy G; Ujfalusi A; Szegedi I; Tiszlavicz LG; Bartyik K; Csanádi K; Péter G; Simon R; Hauser P; Kelemen Á; Sebestyén E; Jakab Z; Matolcsy A; Kiss C; Kovács G; Savola S; Bödör C; Alpár D
Br J Cancer; 2023 Aug; 129(3):455-465. PubMed ID: 37340093
[TBL] [Abstract] [Full Text] [Related]
14. Leukapheresis and Tisagenlecleucel Manufacturing outcomes in Patients Age <3 Years with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Fong D; Tiwari R; Acker C; Clough L; Willert J
Transplant Cell Ther; 2023 Sep; 29(9):579.e1-579.e10. PubMed ID: 37311511
[TBL] [Abstract] [Full Text] [Related]
15. Epidemiology and a Predictive Model of Prognosis Index Based on Machine Learning in Primary Breast lymphoma: Population-Based Study.
Yu Y; Xu Z; Shao T; Huang K; Chen R; Yu X; Zhang J; Han H; Song C
JMIR Public Health Surveill; 2023 Jun; 9():e45455. PubMed ID: 37169516
[TBL] [Abstract] [Full Text] [Related]
16. Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome.
Štach M; Pytlík R; Šmilauerová K; Rychlá J; Mucha M; Musil J; Koladiya A; Nemec M; Petráčková M; Kaštánková I; Pecherková P; Šrámková L; Polgárová K; Trněný M; Lesný P; Vydra J; Otáhal P
Pathol Oncol Res; 2023; 29():1610914. PubMed ID: 37151356
[TBL] [Abstract] [Full Text] [Related]
17. Implication of Dynamin-2 (DNM2) Mutations in Adult T-cell Acute Lymphoblastic Leukemia.
Sobh M; Aref S; Al Agdar M; El Zafrany M; El-Sokkary AMA
Asian Pac J Cancer Prev; 2023 Apr; 24(4):1257-1264. PubMed ID: 37116148
[TBL] [Abstract] [Full Text] [Related]
18. clinical Analysis of Pediatric T-Cell Acute Lymphoblastic Leukemia Using the MRD-Oriented Strategy System.
Xue YJ; Wang Y; Lu AD; Jia YP; Zuo YX; Ding MM; Zeng HM; Zhang LP
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):477-483. PubMed ID: 37080879
[TBL] [Abstract] [Full Text] [Related]
19. The prognostic value of controlling nutritional status (CONUT) score-based nomogram on extranodal natural killer/T cell lymphoma patients.
Zhang S; Sun C; Chen X; Li D; Hu L; Zhang M; Zhang X; Zhang H; Ye J; Wang L; Jia T; Zhu T; Miao Y; Wang C; Wang L; Yan D; Shen Z; Sang W
Ann Hematol; 2023 Jun; 102(6):1433-1442. PubMed ID: 37074377
[TBL] [Abstract] [Full Text] [Related]
20. Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma: J3Zi Study.
Choi I; Okada M; Ito T
Ann Hematol; 2023 May; 102(5):1149-1158. PubMed ID: 36995403
[TBL] [Abstract] [Full Text] [Related]
[Next]